Fig. 5

Oral administration of ISAg induced IL-12 production in antigen-presenting cells via TLR4 signaling. a Yet40 B6 mice were exposed via the oral route using gavage with ISAg (0.5, 1, 2, or 4 mg/injection) or PBS three times per week for 4 weeks. As a positive control, mice were injected (i.p.) with LPS (2 μg) once per week for 4 weeks. b Four weeks later, IL-12p40 (YFP) productions in splenic DCs (CD11c⁺) and macrophages (CD11c⁻CD11b⁺F4/80⁺) were assessed using flow cytometry. c Yet40 B6 mice were received oral ISAg (4 mg/injection) three times per week for 1 to 4 weeks. At the indicated times, IL-12p40 (YFP) productions in splenic DCs and macrophages were assessed using flow cytometry. d C3H/HeN and C3H/HeJ mice were exposed via the oral route to ISAg (4 mg/injection) or PBS three times per week for 4 weeks. Four weeks later, intracellular IL-12p40 production was analyzed in splenic DCs and macrophages using flow cytometry. The mean ± standard deviation values are presented (n = 4 per group; Student’s t-test; *P < 0.05, **P < 0.01). Two-way ANOVA (genotype × treatment) revealed the presence of an interaction between these two factors (^##P < 0.01)